Pemetrexed

Generic Name
Pemetrexed
Brand Names
Alimta, Ciambra, Pemfexy, Pemrydi Rtu, Pemetrexed Fresenius Kabi, Pemetrexed Baxter, Pemetrexed Krka, Pemetrexed medac, Pemetrexed Accord, Pemetrexed Sandoz, Armisarte (previously Pemetrexed Actavis)
Drug Type
Small Molecule
Chemical Formula
C20H21N5O6
CAS Number
137281-23-3
Unique Ingredient Identifier
04Q9AIZ7NO
Background

Pemetrexed is a chemotherapy drug that is manufactured and marketed by Eli Lilly and Company under the brand name Alimta. It is indicated for use in combination with cisplatin for the treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative surgery. Its use in non-small cell lung cancer has also been investigated. Pemetrexed was first approved by the FDA in February 4, 2004.

Indication

Pemetrexed is indicated for the treatment of the following conditions:

Non-squamous non-small cell lung cancer (NSCLC)

Malignant pleural mesothelioma

Associated Conditions
Metastatic Cervical Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Urothelial Carcinoma (UC), Ovarian Cancer, Locally advanced nonsquamous non-small cell lung cancer, Recurrent, metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable Thymoma
Associated Therapies
Monotherapy
Clinical Trials
Related News

A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study

First Posted Date
2018-12-07
Last Posted Date
2024-12-20
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
1000
Registration Number
NCT03768063
Locations
🇺🇸

Univ of Alabama at Birmingham; UAB Comprehensive Cancer Ctr, Birmingham, Alabama, United States

🇺🇸

HonorHealth Research Institute - Pima - Virginia G. Piper Cancer Care Network, Scottsdale, Arizona, United States

🇺🇸

University of Arkansas for Medical Sciences; Winthrop Rockefeller Cancer Institute, Little Rock, Arkansas, United States

and more 199 locations

BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma

First Posted Date
2018-12-03
Last Posted Date
2024-07-09
Lead Sponsor
ETOP IBCSG Partners Foundation
Target Recruit Count
401
Registration Number
NCT03762018
Locations
🇧🇪

CHU Liege, Liege, Belgium

🇫🇷

Le Mans - CHG, Le Mans, France

🇨🇭

Kantonsspital Aarau, Aarau, Switzerland

and more 39 locations

Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM)

First Posted Date
2018-11-30
Last Posted Date
2024-07-16
Lead Sponsor
Abramson Cancer Center at Penn Medicine
Target Recruit Count
20
Registration Number
NCT03760575
Locations
🇺🇸

Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Pemetrexed and Avelumab in Treating Patients With MTAP-Deficient Metastatic Urothelial Cancer

First Posted Date
2018-11-16
Last Posted Date
2024-08-27
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
18
Registration Number
NCT03744793
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer

First Posted Date
2018-11-13
Last Posted Date
2024-11-13
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
10
Registration Number
NCT03737994
Locations
🇺🇸

Miller-Dwan Hospital, Duluth, Minnesota, United States

🇺🇸

Fairview Southdale Hospital, Edina, Minnesota, United States

🇺🇸

Grady Memorial Hospital, Delaware, Ohio, United States

and more 487 locations

Phase 1 Study of INBRX-109 in Subjects with Locally Advanced or Metastatic Solid Tumors Including Sarcomas

First Posted Date
2018-10-23
Last Posted Date
2024-12-12
Lead Sponsor
Inhibrx Biosciences, Inc
Target Recruit Count
321
Registration Number
NCT03715933
Locations
🇺🇸

Precision NextGen Oncology and Research, Beverly Hills, California, United States

🇺🇸

University of California, San Francisco (UCSF), San Francisco, California, United States

🇺🇸

Children's Hospital of Philadelphia- Center for Childhood Cancer Research, Philadelphia, Pennsylvania, United States

and more 31 locations

Carboplatin Plus Pemetrexed Plus Atezolizumab Plus Bevacizumab in Chemotherapy and Immunotherapy-naïve Patients With Stage IV Non-squamous Non-small Cell Lung Cancer

First Posted Date
2018-10-22
Last Posted Date
2023-03-01
Lead Sponsor
Nasser Hanna
Target Recruit Count
30
Registration Number
NCT03713944
Locations
🇺🇸

University of Illinois Cancer Center, Chicago, Illinois, United States

🇺🇸

Indiana Univeristy Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States

🇺🇸

University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States

and more 4 locations

Metformin Plus/Minus Fasting Mimicking Diet to Target the Metabolic Vulnerabilities of LKB1-inactive Lung Adenocarcinoma

First Posted Date
2018-10-17
Last Posted Date
2020-11-16
Lead Sponsor
Marina Garassino
Target Recruit Count
64
Registration Number
NCT03709147
Locations
🇮🇹

Marina Chiara Garassino, Milan, Italy

Rh-Endostatin (Endostar®) Continuous Intravenous Infusion

First Posted Date
2018-10-16
Last Posted Date
2018-10-17
Lead Sponsor
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Target Recruit Count
50
Registration Number
NCT03706703
Locations
🇨🇳

Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, Guangdong, China

Non Squamous NSCLC Patients With Anlotinib Combined With Pemetrexed and Cisplatin

First Posted Date
2018-09-14
Last Posted Date
2018-09-17
Lead Sponsor
Lingyu Luo
Target Recruit Count
62
Registration Number
NCT03671538
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy